Catalyst
Slingshot members are tracking this event:
The FDA set a Prescription Drug User Fee Act (PDUFA) date of October 23, 2017 for Soliris (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 23, 2017
Occurred Source:
http://news.alexionpharma.com/press-release/product-news/fda-approves-soliris-eculizumab-treatment-patients-generalized-myasthenia
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pdufa Date, Soliris, Eculizumab, Refractory Generalized Myasthenia Gravis
